ALDX

Aldeyra Therapeutics Inc

Oct 17 • 04:00PM ET

5.26

-0.13 -2.41 %

Healthcare • Biotechnology • USA • NASD

Peers: NBIX IONS XOMA PRTA CRBP ITCI BHVN AUPH ACAD RIGL

| Held by: VTI IWM VXF IWO VTWO VHT VFMO IWC DFAS ITOT

Index	RUT	P/E	-	EPS (ttm)	-0.85	Insider Own	3.27%	Shs Outstand	60.05M	Perf Week	-2.41%
Market Cap	315.05M	Forward P/E	35.46	EPS next Y	0.15	Insider Trans	-0.99%	Shs Float	57.94M	Perf Month	4.99%
Enterprise Value	248.69M	PEG	-	EPS next Q	-0.24	Inst Own	57.76%	Short Float	8.78%	Perf Quarter	-2.41%
Income	-50.62M	P/S	-	EPS this Y	17.66%	Inst Trans	2.88%	Short Ratio	5.83	Perf Half Y	140.18%
Sales	0.00M	P/B	5.71	EPS next Y	119.16%	ROA	-47.98%	Short Interest	5.09M	Perf YTD	5.41%
Book/sh	0.92	P/C	3.85	EPS next 5Y	-	ROE	-65.91%	52W High	7.20 -26.94%	Perf Year	-1.87%
Cash/sh	1.37	P/FCF	-	EPS past 3/5Y	4.24% 15.99%	ROIC	-91.32%	52W Low	1.14 361.40%	Perf 3Y	0.19%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.83% 5.00%	Perf 5Y	-25.07%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-32.74%	Oper. Margin	-	ATR (14)	0.28	Perf 10Y	0.00%
Dividend Ex-Date	-	Quick Ratio	2.82	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	47.10	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.82	EPS Q/Q	42.63%	SMA20	-1.24%	Beta	0.78	Target Price	9.67
Payout	-	Debt/Eq	0.28	Sales Q/Q	-	SMA50	-3.14%	Rel Volume	0.64	Prev Close	5.39
Employees	9	LT Debt/Eq	0.00	Earnings	Aug 08	SMA200	13.77%	Avg Volume	872.98K	Price	5.26
IPO	May 02, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	33.33% -	Trades		Volume	562,407	Change	-2.41%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-03-24	Upgrade	Oppenheimer	Perform → Outperform	$10
Apr-02-24	Resumed	H.C. Wainwright	Buy	$10
Apr-27-22	Resumed	H.C. Wainwright	Buy	$15
Feb-08-21	Initiated	H.C. Wainwright	Buy	$26
Dec-16-20	Initiated	Berenberg	Buy	$32
Oct-30-20	Initiated	Jefferies	Buy	$24
Oct-16-20	Initiated	BTIG Research	Buy	$29
Sep-22-20	Initiated	Alliance Global Partners	Buy	$32
May-12-20	Initiated	Oppenheimer	Outperform	$12
Dec-04-18	Initiated	Citigroup	Buy	$23
Sep-26-18	Reiterated	Cantor Fitzgerald	Overweight	$23 → $30
Sep-13-18	Initiated	Janney	Buy
Jan-26-18	Initiated	Seaport Global Securities	Buy	$13
Sep-26-16	Initiated	H.C. Wainwright	Buy	$18
Jul-01-16	Initiated	Stifel	Buy	$16
Jul-01-15	Initiated	Canaccord Genuity	Buy	$16
Mar-25-15	Initiated	Chardan Capital Markets	Buy	$16
Mar-20-15	Reiterated	H.C. Wainwright	Buy	$13 → $14
Nov-18-14	Initiated	H.C. Wainwright	Buy	$13
Jun-19-14	Initiated	Aegis Capital	Buy	$35

Show Previous Ratings

Sep-03-25 07:01AM	Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (Business Wire)
Aug-28-25 07:01AM	Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma (Business Wire)
Aug-23-25 04:20AM	JonesTrading Lifts Aldeyra Therapeutics, Inc. (ALDX) Price Target to $9 (Insider Monkey)
Aug-19-25 07:01AM	Aldeyra Therapeutics Receives Fast Track Designation for ADX-2191 for the Treatment of Retinitis Pigmentosa (Business Wire)
Aug-06-25 07:01AM	Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference (Business Wire)
07:00AM	Loading…
Jul-24-25 07:00AM	Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa (Business Wire)
Jul-17-25 09:11AM	Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics (Zacks)
07:00AM	Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease (Business Wire)
Jul-16-25 09:01AM	5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats (Zacks)
Jul-15-25 12:00PM	Aldeyra Therapeutics (ALDX) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
09:40AM	Are Medical Stocks Lagging Amgen (AMGN) This Year? (Zacks)
Jun-26-25 07:00AM	Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma (Business Wire) +10.26%
Jun-17-25 07:00AM	Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease (Business Wire)
May-29-25 07:01AM	Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference (Business Wire)
May-05-25 06:34PM	Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission (Business Wire) -22.22%
04:00PM	Loading…
04:00PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap (Business Wire)
Apr-29-25 11:42AM	Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter Hagens Berman (GlobeNewswire)
Apr-28-25 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm (GlobeNewswire)
Apr-24-25 01:57PM	Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter Hagens Berman (GlobeNewswire) +9.50%
Apr-21-25 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm (GlobeNewswire)
10:52AM	Aldeyra Therapeutics: A Mispriced Gem With Reproxalap's CRL Creating A Golden Buying Opportunity (Seeking Alpha)
08:49AM	Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter Hagens Berman (GlobeNewswire)
Apr-18-25 02:52PM	Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter Hagens Berman (GlobeNewswire)
11:23AM	ALDX INVESTOR NOTICE: Aldeyra Therapeutics, Inc. Investors are Notified to Contact BFA Law About How to Potentially Recover Losses (Newsfile)
Apr-17-25 07:00AM	Aldeyra Therapeutics Appoints Chip Clark to Board of Directors (Business Wire) +8.96%
Apr-16-25 05:23PM	Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter Hagens Berman (GlobeNewswire) -8.64%
Apr-15-25 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm (GlobeNewswire)
Apr-11-25 01:26PM	Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter Hagens Berman (GlobeNewswire)
07:43AM	ALDX STOCK NOTIFICATION: Did Aldeyra Therapeutics, Inc. Violate the Securities Laws? Investors are Notified to Contact BFA Law (NASDAQ:ALDX) (GlobeNewswire)
Apr-10-25 09:30AM	Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter - Hagens Berman (PR Newswire)
05:00PM	Loading…
Apr-09-25 05:00PM	Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter Hagens Berman (GlobeNewswire)
Apr-08-25 04:51AM	After A CRL Setback, Aldeyra Therapeutics Is A Compelling Speculative Buy (Seeking Alpha)
03:08AM	ALDX SECURITIES NOTIFICATION: Aldeyra Therapeutics, Inc. Investors that Suffered Losses are Notified to Contact BFA Law (Newsfile)
Apr-06-25 07:08AM	ALDX SECURITIES NOTICE: Aldeyra Therapeutics, Inc. Investors with Losses are Notified to Contact BFA Law as they may have been Affected by Securities Violations (Newsfile)
Apr-03-25 10:24AM	Aldeyra Therapeutics Stock Craters to All-Time Low on FDA Letter (Investopedia) -73.33%
08:00AM	Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease (Business Wire)
Mar-10-25 07:00AM	Aldeyra Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference (Business Wire)
Feb-05-25 03:24AM	Aldeyra Therapeutics, Inc. (ALDX) Notice: Grabar Law Office Is Investigating Claims for Long-Term Shareholders (Newsfile) +6.73%
Feb-04-25 07:00AM	Aldeyra Therapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference (Business Wire)
Jan-20-25 03:28PM	Is Aldeyra Therapeutics (ALDX) Among Billionaire Joseph Edelman's Long-Term Stock Picks? (Insider Monkey)
Dec-09-24 10:05AM	Is the Options Market Predicting a Spike in Aldeyra Therapeutics (ALDX) Stock? (Zacks)
Dec-02-24 07:00AM	Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference (Business Wire)
Nov-18-24 07:00AM	Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement (Business Wire) +11.64%
Nov-14-24 07:00AM	Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference (Business Wire)
Oct-31-24 07:00AM	Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting (Business Wire)
Oct-03-24 07:00AM	Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease (Business Wire)
Sep-05-24 07:00AM	Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-30-24 10:38AM	Aldeyra Therapeutics Inc (NASDAQ:ALDX) A Bull Case Theory (Insider Monkey) +7.07%
Aug-09-24 06:32AM	Aldeyras Phase III clinical trial of Reproxalap meets primary endpoint (Clinical Trials Arena) +21.72%
Aug-08-24 07:00AM	Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap (Business Wire) +28.53%
Aug-07-24 04:01PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap (Business Wire) -5.23%
Jun-20-24 07:00AM	Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable (Business Wire) -6.47%
Jun-14-24 06:32AM	Aldeyra Therapeutics concludes subject enrolment in dry eye disease trial (Clinical Trials Arena)
Jun-13-24 07:00AM	Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease (Business Wire)
Jun-12-24 07:00AM	Aldeyra Therapeutics to Host Investor Roundtable Q&A (Business Wire)
May-29-24 07:00AM	Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference (Business Wire)
May-14-24 09:40AM	Is Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year? (Zacks) +12.70%
May-08-24 03:12PM	Aldeyra Therapeutics Enrolls First Patient in Phase 3 Dry Eye Chamber Study (MT Newswires)
07:00AM	Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease (Business Wire)
May-03-24 08:52AM	ALDX Stock Earnings: Aldeyra Therapeutics Meets EPS for Q1 2024 (InvestorPlace)
Apr-25-24 07:00AM	Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day (Business Wire)
Apr-22-24 09:40AM	Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year? (Zacks)
Apr-18-24 07:00AM	Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024 (Business Wire)
Apr-06-24 06:37AM	Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why (Zacks)
Apr-04-24 12:36PM	Health Care Roundup: Market Talk (The Wall Street Journal) +12.89%
Apr-03-24 02:58PM	Aldeyra's Dry Eye Disease Drug May Be on Path for FDA Approval (Barrons.com) +16.90%
Mar-28-24 07:00AM	Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease (Business Wire) +6.17%
Mar-27-24 01:21PM	Notice to Long-Term Aldeyra Therapeutics, Inc. (ALDX) Investors (Newsfile) +5.48%
Mar-13-24 02:33AM	Aldeyra Therapeutics Inc President and CEO Todd Brady Sells Company Shares (GuruFocus.com)
Mar-06-24 09:40AM	Here's Why You Should Invest in Aldeyra (ALDX) Stock Now (Zacks)
Feb-06-24 07:00AM	Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (Business Wire) +7.05%
Jan-04-24 07:00AM	Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases (Business Wire)
Dec-19-23 07:27AM	UPDATE 1-Aldeyra Therapeutics' skin disease drug succeeds in mid-stage study (Reuters) +18.58%
07:05AM	Aldeyra Therapeutics' eczema drug succeeds in mid-stage study (Reuters)
07:00AM	Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX629 in Patients with Atopic Dermatitis (Business Wire)
Dec-18-23 04:01PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis (Business Wire)
Dec-06-23 11:55AM	13 Hot Penny Stocks To Buy According to Hedge Funds (Insider Monkey)
Dec-05-23 09:00AM	Should You Buy Aldeyra Therapeutics (ALDX) Ahead of Earnings? (Zacks)
Nov-27-23 04:07PM	Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease (Business Wire)
Nov-01-23 10:34AM	Why Is Aldeyra Therapeutics (ALDX) Stock Up 40% Today? (InvestorPlace) +48.54%
07:05AM	Aldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize Reproxalap (Business Wire)
Oct-18-23 08:30AM	Biotech Stock Roundup: ALDX, EVLO Down on Setback, SRRK Offers Updates & More (Zacks) -5.98%
Oct-17-23 10:13AM	Aldeyra (ALDX) Plummets on Dry Eye Disease Drug's Setback (Zacks)
Aug-28-23 10:22AM	15 Most Shorted Stocks That Are Loved By Analysts (Insider Monkey)
Jul-20-23 09:55AM	Can Aldeyra Therapeutics, Inc. (ALDX) Climb 107.66% to Reach the Level Wall Street Analysts Expect? (Zacks)
Jul-06-23 07:00AM	Aldeyra Therapeutics to Participate in SVB Securities Therapeutics Forum (Business Wire)
Jun-29-23 07:00AM	Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Clinical Trial of ADX2191 in Patients with Retinitis Pigmentosa (Business Wire)
05:20AM	The Petri Dish: Startup behind VR treatments gets $16M, Aldeyra notches midstage trial win (American City Business Journals)
Jun-28-23 04:01PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX-2191 in Patients with Retinitis Pigmentosa (Business Wire)
Jun-27-23 12:03PM	Aldeyra Therapeutics' Chronic Cough Potential Shows Significant Reduction In Cough Frequency Versus Placebo (Benzinga)
07:00AM	Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX629 in Patients With Chronic Cough (Business Wire)
Jun-26-23 04:01PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX629 in Patients with Chronic Cough (Business Wire) +5.63%
Jun-23-23 07:00AM	Aldeyra Therapeutics to Join the Russell 2000® and Russell 3000® Indexes (Business Wire) -8.26%
Jun-21-23 09:34AM	Aldeyra Therapeutics Provides Regulatory Update on ADX-2191 (Business Wire) -27.44%
Jun-16-23 10:26AM	Aldeyra (ALDX) Up On Positive Data From Conjunctivitis Study (Zacks)
Jun-15-23 02:52PM	Why Aldeyra Therapeutics Stock Is Trading Higher Today (Benzinga)
07:08AM	Aldeyra Therapeutics eye treatment meets late-stage study main goal (Reuters)
07:00AM	Aldeyra Therapeutics Announces Achievement of Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE2 Trial of Reproxalap in Allergic Conjunctivitis (Business Wire)
Jun-14-23 04:01PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 INVIGORATE2 Trial in Allergic Conjunctivitis (Business Wire)
Jun-02-23 07:00AM	Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference (Business Wire)

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Alfieri Michael	Principal Financial Officer	Aug 13 '25	Buy	5.30	2,500	13,250	2,500	Aug 15 04:09 PM
Machatha Stephen	Chief Development Officer	Aug 11 '25	Sale	5.15	22,073	113,713	221,799	Aug 13 06:03 PM
Machatha Stephen	Officer	Aug 12 '25	Proposed Sale	5.26	22,074	116,109		Aug 12 05:50 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Apr 03 '25	Sale	1.42	3,400,000	4,828,000	5,875,851	Apr 07 06:43 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALDX

Aldeyra Therapeutics Inc

Upgrade your FINVIZ experience